The active pharmaceutical ingredient (API) is the most crucial biologically active thing in pharmaceutical products, contributing to their healing consequences. APIs, produced via chemical synthesis or derived from herbal resources, maintain an essential function within the global pharmaceutical supply chain, forming the basis for drug improvement and manufacturing. The demand for classy APIs is predicted to rise because the pharmaceutical industry progresses towards superior therapeutics and progressive delivery systems.
Various factors, consisting of the expansion of capacities in the pharmaceutical and biopharmaceutical sectors, the growing dependence on generics and medical knowledge, improvements in the API manufacturing era, and the growing age of the worldwide population, affect the market for APIs. The growing incidence of chronic disease like cardiovascular conditions and most cancers similarly boosts the market's boom.
The rising burden of chronic illnesses is increasing the need for effective tablets. The American Cancer Society predicts around 2,001,140 new cancer instances in the United States in 2024.
Numbers of Chronic Diseases worldwide
- According to the US Department of Health and Human Services, an estimated 129 million people in the US had at least one major chronic disease in February 2024.
- According to a July 2023 analysis, the prevalence of 19 out of 20 health conditions in England is expected to increase by 2040, including a 30% increase in the number of people with cancer, diabetes, and kidney disease. This means that the number of people with major diseases is expected to increase from almost 1 in 6 adults in 2019 to nearly 1 in 5 by 2040.
- According to the Antidiskriminierungsstelle, approximately one in six individuals in Germany live with a chronic illness or severe disability.
- About 38% of French adults reported having at least one chronic condition in 2019, slightly higher than the EU average.
- In 2030, around 7 million people in the Netherlands will be living with chronic disease due to population aging.
- In November 2022, a study found that 81.1% of older adults in China - 179.9 million - have chronic diseases. The prevalence increases with age, peaking at 87.2% in people aged 80-84.
- According to a 2023 study, over 90% of Japanese adults aged 75 or older have at least one chronic disease, and about 80% of them have multiple chronic diseases.
- According to a NITI Aayog report from February 2024, 75% of India's elderly population suffers from one or more chronic diseases.
India and China have emerged as unrivaled giants in the API market
India and China are main key players in the API production industry due to their cost-effective capabilities. Their lower manufacturing costs, lenient environmental regulations, and cost-effective labor make them attractive alternatives to the United States. Additionally, they have robust testing capabilities, research opportunities, and favorable regulatory audits, giving them a competitive edge in developing markets. This creates opportunities for the industry to enhance efficiency and productivity by scaling up production in these markets.- Piramal Pharma Limited launched a new API plant in Aurora, Ontario, in July 2022.
Active Pharmaceutical Ingredients (API) Industry Overview
The top companies in the global active pharmaceutical ingredients (API) industry are Pfizer, Inc., Novartis International AG, Sanofi, Boehringer Ingelheim, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., ELI Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., and Abbvie Inc.Active Pharmaceutical Ingredients (API) Industry News
- In December 2023, Novo Nordisk announced plans to build a new active pharmaceutical ingredients facility in Kalundborg, Denmark, to expand its manufacturing capacity.
- In October 2023, IQuest Enterprises signed a binding contract to acquire Viatris's Indian active pharmaceutical ingredients (API) business.
- In October 2023, Clariant expanded its pharmaceutical ingredient solutions portfolio to include three new VitiPure® excipients designed to facilitate the development of safe and efficient medications, including sensitive formulations like mRNA vaccines and biologic medications.
- In September 2023 - Glenmark Pharmaceuticals and Nirma Limited entered into a share purchase agreement for Glenmark Lifesciences.
- In July 2023 - Teva is considering selling a $2 billion unit of active ingredients.
Drug Type - Market is broken up into 2 viewpoints:
1. Innovative2. Generic
Synthesis - Market is broken up into 2 viewpoints:
1. Synthetic2. Biotech
Type of Manufacturer - Market is broken up into 2 viewpoints:
1. Captive2. Merchant
Application - Market is broken up into 11 viewpoints:
1. Cardiovascular Diseases2. Oncology
3. Central Nervous System and Neurology
4. Orthopedic
5. Endocrinology
6. Pulmonology
7. Gastroenterology
8. Nephrology
9. Ophthalmology
10. Other Applications
Countries - Market of 25 Countries Covered:
1. North America1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
All companies have been covered from 3 viewpoints:
- Overview
- Recent Development
- Revenue
Company Analysis:
1. Pfizer, Inc.2. Novartis International AG
3. Sanofi
4. Boehringer Ingelheim
5. Bristol-Myers Squibb
6. Teva Pharmaceutical Industries Ltd.
7. ELI Lilly and Company
8. GlaxoSmithKline
9. Merck & Co., Inc.
10. Abbvie Inc.
Table of Contents
Companies Mentioned
- Pfizer, Inc.
- Novartis International AG
- Sanofi
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Teva Pharmaceutical Industries Ltd.
- ELI Lilly and Company
- GlaxoSmithKline0
- Merck & Co., Inc.
- Abbvie Inc.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 235 |
| Published | June 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 212.12 Billion |
| Forecasted Market Value ( USD | $ 377.05 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
